For example, continuous intrapleural IL2 infusion has also been evaluated in clinical trials for the treatment of mesothelioma, and intrapleural cavity IL2 levels were measured to be 6000-fold higher than systemic leading to improvements in objective response rate and disease control rate (63, 64). This evidence concerns the gene IL2 and mesothelioma.